RxDoctor Payments Data

Chidinma Aniemeke, MD

Geriatric Medicine · San Antonio, TXNPI 1811215494

Payments from drug & device makers

$512in general payments, 2019–2025

Across 8 payments — averaging $63.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Geistlich Pharma, North America, Inc.$192
  • Sunovion Pharmaceuticals Inc.$82
  • Merck$80
  • Johnson & Johnson$50
  • Otsuka America Pharmaceutical, Inc.$50
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$42
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$512 in reported general payments places this provider in the 65th percentile of 275 geriatric medicine providers in Texas.

See all geriatric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$107,679
Medicare patients
349
Services billed
1,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$74,979
EliquisApixaban94$49,887
JardianceEmpagliflozin49$42,397
FarxigaDapagliflozin Propanediol34$28,979
TrulicityDulaglutide22$26,923
JanuviaSitagliptin Phosphate22$24,528
MounjaroTirzepatide15$18,332
RybelsusSemaglutide15$15,494
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,791
MyrbetriqMirabegron25$11,663
Memantine Hcl ErMemantine Hcl26$3,847
Memantine Hcl115$3,571
Levothyroxine Sodium232$3,128
Gabapentin132$2,813
Duloxetine Hcl87$2,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$80$24,52822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 275 geriatric medicine providers in Texas.

Other geriatric medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →